Bioprinting of patient-derived in vitro intrahepatic cholangiocarcinoma tumor model: establishment, evaluation and anti-cancer drug testing
Source abstract
Abstract
Abstract Towards the development of in vivo -mimicking tumor model for extensive study of tumorigenesis and establishment of personalized therapy, patient-derived primary tumor cells were employed in this work for three-dimensional (3D) bioprinting. Intrahepatic cholangiocarcinoma cells isolated from patient were bioprinted using a composite hydrogel system of gelatin-alginate-Matrigel TM into pre-designed grid architecture. ICC cells were observed to process a colony forming ability with high survival rate and active proliferation. Expression levels of tumor markers, cancer stem cell markers, matrix metalloproteinase protein, index of tumor fibrosis, index of liver function, and epithelial-mesenchymal transition regulatory proteins confirmed the development of the invasive and metastatic phenotype of the intrahepatic cholangiocarcinoma cells in the 3D printed tumor microenvironment. Similar results were obtained in anti-cancer drug resistance of the intrahepatic cholangiocarcinoma cells in the 3D bioprinted construct that demonstrated stem-like properties, which suggested the promising potential of current 3D printed tumor model in the development of personalized therapy, especially for discovery of more conducive targeted drugs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Cells and Metastasis · Oral and Maxillofacial Pathology · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma10.3892/or.2013.2290 ↗
2. Advances in the diagnosis and treatment of patients with intrahepatic cholangiocarcinoma10.1245/s10434-019-07873-z ↗
3. Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study10.1053/j.gastro.2004.12.048 ↗
4. Intrahepatic cholangiocarcinoma: socioeconomic discrepancies, contemporary treatment approaches and survival trends from the national cancer database10.1245/s10434-019-07175-4 ↗
5. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?10.1016/j.jhep.2003.11.030 ↗
6. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer10.3892/or.2015.3767 ↗
7. 3D bioprinting for drug discovery and development in pharmaceutics10.1016/j.actbio.2017.05.025 ↗
8. Lost in translation: animal models and clinical trials in cancer treatment10.2147/OTT.S64230 ↗
9. Animal models of human disease: challenges in enabling translation10.1016/j.bcp.2013.08.006 ↗
10. 3D bioprinting: improvingin vitro models of metastasis with heterogeneous tumor microenvironments10.1242/dmm.025049 ↗
11. 3D printing for the development of in vitro cancer models10.1016/j.cobme.2017.06.003 ↗
12. Three-dimensional culture systems in cancer research: focus on tumor spheroid model10.1016/j.pharmthera.2016.03.013 ↗
13. A three-dimensional spheroidal cancer model based on PEG-fibrinogen hydrogel microspheres10.1016/j.biomaterials.2016.10.052 ↗
14. Three-dimensional bioprinting of embryonic stem cells directs highly uniform embryoid body formation10.1088/1758-5090/7/4/044101 ↗
15. Controlled positioning of cells in biomaterials—approaches towards 3D tissue printing10.3390/jfb2030119 ↗
16. Application areas of 3D bioprinting10.1016/j.drudis.2016.04.006 ↗
17. Strategy for the 3D bioprinting of hydrogels from nonviscous photo-crosslinkable inks10.1002/adma.201604983 ↗
18. Advanced biomaterials and microengineering technologies to recapitulate the stepwise process of cancer metastasis10.1016/j.biomaterials.2017.04.017 ↗
19. Three-dimensional printing of Hela cells for cervical tumor model in vitro10.1088/1758-5082/6/3/035001 ↗
20. Rapid 3D extrusion of synthetic tumor microenvironments10.1002/adma.201501729 ↗
21. 3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility10.1088/1758-5090/8/4/045005 ↗
22. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance10.1073/pnas.1111840108 ↗
23. Phenotypic instability of Saos-2 cells in long-term culture10.1016/j.bbrc.2005.05.097 ↗
24. Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line10.1186/s12935-016-0322-5 ↗
25. A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy10.1038/s41551-019-0363-x ↗
26. Modeling tumor phenotypes in vitro with three-dimensional bioprinting10.1016/j.celrep.2018.12.090 ↗
27. Intrahepatic cholangiocarcinoma: management options and emerging therapies10.1016/j.jamcollsurg.2013.05.021 ↗
28. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma10.1016/j.canlet.2016.02.038 ↗
29. Effect of bioink properties on printability and cell viability for 3D bioplotting of embryonic stem cells10.1088/1758-5090/8/3/035020 ↗
30. Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection10.1155/2013/380797 ↗
31. Prospective identification of tumorigenic breast cancer cells10.1073/pnas.0530291100 ↗
32. Role of cancer stem cells in cholangiocarcinoma and therapeutic implications10.3390/ijms20174154 ↗
33. EpCAM and the biology of hepatic stem/progenitor cells. American journal of physiology10.1152/ajpgi.00069.2014 ↗
34. Potential mechanisms of CD133 in cancer stem cells10.1016/j.lfs.2017.07.008 ↗
35. Cancer stem cells: models, mechanisms and implications for improved treatment10.4161/cc.7.10.5953 ↗